2014-04-03 15:03:01 -
Novaliq GmbH today announced the commencement of a Phase 1 study for CyclASol (Cyclosporin solution) following US and European patent approval of the solution for the treatment of dry eye syndrome.
While conventional cyclosporin formulations are emulsions, CyclASol is the first and only 0.05% clear cyclosporin solution. CyclASol is available in multi-dose and preservative free bottles for the treatment of dry eye syndrome. CyclASol has demonstrated long-term stability plus superior wettability, pharmacokinetics, and biocompatibility compared to conventional emulsions.
CyclASol was developed from Novaliq’s broad range Semi Fluorinated Alkane (SFA) drug delivery platform EyeSol®, offering significant competitive advantages for multiple drug candidates within ophthalmology, primarily by enhancing the therapeutic effect of poorly soluble drugs.
“We are pleased to receive the USA & European patent
and to announce the start of phase 1 CyclASol study,” said Bernhard Günther, CEO of Novaliq GmbH. “These are both significant new milestones for Novaliq as we build our innovative drug delivery portfolio.” In 2013 Novaliq finalized their fifth round of financing for €13.9 million ($18.1 million) with the intent to strengthen both their prescription and OTC product development programs based on SFA technology.
“We congratulate Novaliq on obtaining patent approval for CyclASol and start of their clinical trials,” commented Mathias Hothum, Managing Director of Dievini Hopp BioTech Holding GmbH & Co. KG, the investment company of SAP co-founder Dietmar Hopp. “We are pleased to support Novaliq as it pioneers new topical ocular drug delivery technology. We endorse Novaliq’s strategy to establish a portfolio of consumer and prescription product portfolios within ophthalmology. These products are intended to cover unmet needs with one major advantage being they will be preservative free,” Mathias Hothum added furthermore.
About Novaliq GmbHNovaliq is a drug delivery company whose goal is to develop innovative pharmaceutical formulations. Its patented semifluorinated alkanes (SFAs) can be used in various routes of administration for the transport of drugs or oxygen for therapeutic purposes. Novaliq currently develops innovative ophthalmic formulations as well as solutions for organ preservation and has several product candidates with excellent market potential in various stages of development. Novaliq welcomes invitations from interested parties to enter into discussions about significant additional development or partnership opportunities.
About Dievini Hopp BioTech Holding GmbH & Co. KGDievini is an active investor in Life and Health Sciences companies, with a focus on innovative therapeutics and diagnostics shown to lead to novel treatment regimens allowing doctors to treat patients with life-threatening diseases more safely and efficiently than they are currently able.
" title="http://cts.businesswire.com/ct/CT?id=bwnews&sty=20140403005139r1&sid=16929&distro=ftp\"/>" target="_blank" rel="nofollow">cts.businesswire.com/ct/CT?id=bwnews&sty=20140403005139r1&am ..
Contact USAScotia Vision ConsultantsMichael O’Rourke,
: mailto:email@example.com orContact
EuropeNovaliq GmbHBernhard Günther, CEO, + 49 6221 502